These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25596534)

  • 21. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
    Layoun ME; Wickramasinghe CD; Peralta MV; Yang EH
    Curr Oncol Rep; 2016 Jun; 18(6):35. PubMed ID: 27113369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.
    Jones RL; Ewer MS
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1249-69. PubMed ID: 17020459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial.
    Minotti G; Menna P; Calabrese V; Greco C; Armento G; Annibali O; Marchesi F; Salvatorelli E; Reggiardo G
    J Pharmacol Exp Ther; 2019 Aug; 370(2):197-205. PubMed ID: 31101682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies to prevent and treat cardiovascular risk in cancer patients.
    Cardinale D; Bacchiani G; Beggiato M; Colombo A; Cipolla CM
    Semin Oncol; 2013 Apr; 40(2):186-98. PubMed ID: 23540744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiotoxicity of Cancer Chemotherapy - Mechanisms and Therapeutic Approach].
    Akazawa H
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2058-2063. PubMed ID: 29361617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.
    O'Hare M; Sharma A; Murphy K; Mookadam F; Lee H
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):511-8. PubMed ID: 25843285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardio-oncology: the new frontier of clinical and preventive cardiology.
    Paris S; Tarantini L; Navazio A; Faggiano P
    Monaldi Arch Chest Dis; 2020 Jun; 90(2):. PubMed ID: 32571000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardio-oncology: management of cardiovascular toxicity.
    Markman TM; Markman M
    F1000Res; 2019; 8():. PubMed ID: 30755794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management of Cancer Patients with Cardiovascular Complications - Onco-Cardiology].
    Mukai M
    Gan To Kagaku Ryoho; 2016 Aug; 43(8):940-4. PubMed ID: 27539035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention and management of cardiotoxicity from antineoplastic therapy.
    Chanan-Khan A; Srinivasan S; Czuczman MS
    J Support Oncol; 2004; 2(3):251-6; discussion 259-61, 264-6. PubMed ID: 15328825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Early detection of anthracyclines cardiotoxicity by tissue Doppler echocardiography about 45 cases at Abidjan institute of cardiology].
    Pio M; Adoubi K; Adoh A; Didi-Kouko C; Anzouan-Kacou JB; Tegnan A; Adoubi I
    Ann Cardiol Angeiol (Paris); 2013 Feb; 62(1):28-33. PubMed ID: 22513244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
    Yeh ET; Tong AT; Lenihan DJ; Yusuf SW; Swafford J; Champion C; Durand JB; Gibbs H; Zafarmand AA; Ewer MS
    Circulation; 2004 Jun; 109(25):3122-31. PubMed ID: 15226229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac toxicity from systemic cancer therapy: a comprehensive review.
    Curigliano G; Mayer EL; Burstein HJ; Winer EP; Goldhirsch A
    Prog Cardiovasc Dis; 2010; 53(2):94-104. PubMed ID: 20728696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review.
    Serini S; Ottes Vasconcelos R; Nascimento Gomes R; Calviello G
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29231904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review.
    Berardi R; Caramanti M; Savini A; Chiorrini S; Pierantoni C; Onofri A; Ballatore Z; De Lisa M; Mazzanti P; Cascinu S
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):75-86. PubMed ID: 23522920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.
    Albini A; Pennesi G; Donatelli F; Cammarota R; De Flora S; Noonan DM
    J Natl Cancer Inst; 2010 Jan; 102(1):14-25. PubMed ID: 20007921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Routine Prophylactic Cardioprotective Therapy Should Not Be Given to All Recipients of Potentially Cardiotoxic Cancer Chemotherapy.
    Davis MK; Virani SA
    Can J Cardiol; 2016 Jul; 32(7):926-30. PubMed ID: 27245087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention.
    Cadeddu Dessalvi C; Deidda M; Mele D; Bassareo PP; Esposito R; Santoro C; Lembo M; Galderisi M; Mercuro G
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):315-323. PubMed ID: 29708912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology.
    Minotti G; Menna P; Camilli M; Salvatorelli E; Levi R
    Adv Pharmacol; 2022; 94():365-409. PubMed ID: 35659376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.